Skip to main content

Animations

MJFF Publications

3771 - 3780 of 8808 Results
Title
Year
  • Year
  • 2022
  • 2021
  • 2022
  • 2022
  • 2022
  • 2022
  • 2021
  • 2021
  • 2021
  • 2021
  • Summary Details
    RESTRICTED
    Title: The protean roles of neuroinflammation in trauma, infections, autoimmunity and neurodegeneration
    Journal Name: Seminars in Immunology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.smim.2022.101655
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging
    Journal Name: Seminars in Arthritis and Rheumatism
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.semarthrit.2021.08.004
    Citation Count: 23
  • Summary Details
    OPEN
    Title: An economic evaluation of the NightWatch for children with refractory epilepsy: Insight into the cost-effectiveness and cost-utility
    Journal Name: Seizure: European Journal of Epilepsy
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.seizure.2022.08.003
    Citation Count: 7
  • Summary Details
    RESTRICTED
    Title: Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00400-8
    Citation Count: 145
  • Summary Details
    RESTRICTED
    Title: Revisiting levodopa for advanced Parkinson's disease
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00435-5
    Citation Count: 1
  • Summary Details
    RESTRICTED
    Title: Major advances in Parkinson's disease over the past two decades and future research directions
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3
    Citation Count: 13
  • Summary Details
    RESTRICTED
    Title: Movement disorders research in 2021: cracking the paradigm
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00413-0
    Citation Count: 18
  • Summary Details
    RESTRICTED
    Title: Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00368-9
    Citation Count: 54
  • Summary Details
    OPEN
    Title: Prehospital scales in acute ischaemic stroke management – Authors' reply
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00169-1
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30449-x
    Citation Count: 251
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.